Cargando…

Ventricular arrhythmias not meeting criteria for terminating cardiopulmonary exercise testing stratify prognosis and disease severity in heart failure of preserved, midrange, and reduced ejection fraction

BACKGROUND: Continued high mortality in heart failure patients indicates the need for additional methods of risk stratification and phenotyping. HYPOTHESIS: We hypothesized that ventricular arrhythmias that do not meet test‐termination criteria (non‐terminating ventricular arrhythmias [NTVA]) during...

Descripción completa

Detalles Bibliográficos
Autores principales:	Popovic, Dejana, Arena, Ross, Jakovljevic, Djordje, Ristic, Arsen, Guazzi, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc. 2020
Materias:	Clinical Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368295/ https://www.ncbi.nlm.nih.gov/pubmed/32271482 http://dx.doi.org/10.1002/clc.23367

Ejemplares similares

Prognostic Value of Cardiopulmonary Exercise Testing in Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction
por: Nadruz, Wilson, et al.
Publicado: (2017)

The Role of Cardiopulmonary Exercise Testing in Hypertrophic Cardiomyopathy
por: Mikic, Lidija, et al.
Publicado: (2023)

Novel Mechanisms in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction
por: Lakhani, Ishan, et al.
Publicado: (2019)

Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction
por: Vergaro, Giuseppe, et al.
Publicado: (2019)

Mode of Death Among Japanese Adults With Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction
por: Kitai, Takeshi, et al.
Publicado: (2020)

Heart Failure With Midrange Ejection Fraction: Prior Left Ventricular Ejection Fraction and Prognosis
por: Zhang, Xinxin, et al.
Publicado: (2021)

Comorbidities, Fragility, and Quality of Life in Heart Failure Patients With Midrange Ejection Fraction
por: Gastelurrutia, Paloma, et al.
Publicado: (2018)

Type 2 Diabetes Mellitus and Chronic Heart Failure with Midrange and Preserved Ejection Fraction: A Focus on Serum Biomarkers of Fibrosis
por: Lebedev, D. A., et al.
Publicado: (2020)

Cisplatin-induced cardiotoxicity with midrange ejection fraction: A case report and review of the literature
por: Hu, Yang, et al.
Publicado: (2018)

Right Heart Phenotype in Heart Failure With Preserved Ejection Fraction
por: Guazzi, Marco, et al.
Publicado: (2021)

Left Ventricular Remodeling Risk Predicted by Two-Dimensional Speckle Tracking Echocardiography in Acute Myocardial Infarction Patients with Midrange or Preserved Ejection Fraction in Western Romania
por: Bordejevic, Diana Aurora, et al.
Publicado: (2021)

H(2)FPEF score predicts atherosclerosis presence in patients with systemic connective tissue disease
por: Vasilev, Vladimir, et al.
Publicado: (2021)

Sudden Death and Ventricular Arrhythmias in Heart Failure With Preserved Ejection Fraction
por: Cho, Jae Hyung
Publicado: (2022)

Efficacy and safety of sacubitril valsartan in treating heart failure with midrange ejection fraction after acute myocardial infarction in diabetic patients
por: Ye, Fanhao, et al.
Publicado: (2022)

The Safety of The Directly Acting Antiviral Treatment For Hepatitis C Virus According To The Egyptian National Program Protocol In Patients With Midrange Ejection Fraction
por: Alaarag, Ahmed Farouk, et al.
Publicado: (2021)

Differential Response to Interleukin‐1 Blockade With Anakinra on Cardiorespiratory Fitness in Patients With Heart Failure With Preserved Ejection Fraction Stratified According to Left Ventricular Ejection Fraction
por: Golino, Michele, et al.
Publicado: (2023)

Racial differences of heart failure with midrange ejection fraction (HFmrEF): a large urban centre-based retrospective cohort study in the USA
por: Li, Dan Leslie, et al.
Publicado: (2019)

The alpha-melanocyte stimulating hormone is related to heart rate during exercise recovery
por: Popovic, Dejana, et al.
Publicado: (2020)

Haemodynamic determinants of quality of life in chronic heart failure
por: Fatrin, Serlie, et al.
Publicado: (2022)

Different Pathophysiology and Outcomes of Heart Failure With Preserved Ejection Fraction Stratified by K-Means Clustering
por: Harada, Daisuke, et al.
Publicado: (2020)

Distinctive prognostic factor of heart failure with preserved ejection fraction stratified with admission blood pressure
por: Nakagawa, Akito, et al.
Publicado: (2021)

Follow‐up after hemodynamically not tolerated ventricular tachycardia in patients with midrange reduced to normal ejection fraction: A retrospective single‐centre case series
por: Groeneveld, Sanne A., et al.
Publicado: (2020)

Surgical treatment of patients with aortic valve disease complicated with moderate functional mitral regurgitation and heart failure with midrange ejection fraction: a cohort study
por: Zhao, Wei, et al.
Publicado: (2022)

Are arrhythmias the drivers of sudden cardiac death in heart failure with preserved ejection fraction? A review
por: Yuyun, Matthew F., et al.
Publicado: (2022)

Stratified Treatment of Heart Failure with preserved Ejection Fraction: rationale and design of the STADIA‐HFpEF trial
por: Scheffer, Mariëlle, et al.
Publicado: (2020)

Guideline‐Directed Medical Therapy for Patients With Heart Failure With Midrange Ejection Fraction: A Patient‐Pooled Analysis From the KorHF and KorAHF Registries
por: Choi, Ki Hong, et al.
Publicado: (2018)

Magnetostriction Enhancement in Midrange Modulus Magnetorheological Elastomers for Sensor Applications
por: Tasin, Muhammad Asyraf, et al.
Publicado: (2023)

Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction
por: Löfström, Ulrika, et al.
Publicado: (2019)

In-hospital Outcomes and Arrhythmia Burden in Patients with Obstructive Sleep Apnea and Heart Failure with Preserved Ejection Fraction
por: Gill, Jashan, et al.
Publicado: (2022)

The effect of angiotensin-converting enzyme inhibitors on clinical outcomes in patients with ischemic cardiomyopathy and midrange ejection fraction: a post hoc subgroup analysis from the PEACE trial
por: Alzahrani, Talal, et al.
Publicado: (2018)

Cardiopulmonary assessment of patients diagnosed with Gaucher’s disease type I
por: Bjelobrk, Marija, et al.
Publicado: (2021)

Diagnostic utility of sub-maximum cardiopulmonary exercise testing in the ambulatory setting for heart failure with preserved ejection fraction
por: Oakland, Hannah T., et al.
Publicado: (2020)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease, and Heart Failure with Preserved Ejection Fraction: A Cardiopulmonary Perspective
por: Mehmood, Muddassir
Publicado: (2020)

A prospective evaluation of the established criteria for heart failure with preserved ejection fraction using the Alberta HEART cohort
por: Ezekowitz, Justin A., et al.
Publicado: (2017)

Use of the Left Ventricular Internal Dimension at End-Diastole and the E-Point Septal Separation Ratio in the Prediction of the Left Ventricular Systolic Function in Patients with Midrange and Reduced Ejection Fractions: A Pilot Study
por: Cosansu, Kahraman, et al.
Publicado: (2019)

Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy
por: Tafelmeier, Maria, et al.
Publicado: (2020)

Impact of Atrial Fibrillation on Exercise Capacity and Mortality in Heart Failure With Preserved Ejection Fraction: Insights From Cardiopulmonary Stress Testing
por: Elshazly, Mohamed B., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hkbq48j2gm8466ge3tbbea4du4